Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.58 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.58 |
| ▸ | PDE5A | O76074 | 8/20 | 0.55 |
| ▸ | GUCY1A1 | Q02108 | 10/20 | 0.49 |
| ▸ | GUCY1B1 | Q02153 | 10/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL417331 | 0.94 | ADORA3 (0.60) | ADORA3KCNH2PDE5AGUCY1A1GUCY1B1 | |
| SCHEMBL29382996 | 0.94 | ADORA3 (0.60) | ADORA3KCNH2PDE5AGUCY1A1GUCY1B1 | |
| SCHEMBL174678 | 0.86 | ADORA3 (0.65) | ADORA3KCNH2PDE5AGUCY1A1GUCY1B1 | |
| SCHEMBL10252555 | 0.85 | ADORA3 (0.62) | ADORA3KCNH2PDE5AGUCY1A1GUCY1B1 | |
| SCHEMBL15745639 | 0.84 | ADORA3 (0.65) | ADORA3KCNH2PDE5AGUCY1A1GUCY1B1 | |
| SCHEMBL29154434 | 0.82 | ADORA3 (0.68) | ADORA3KCNH2PDE5AGUCY1A1GUCY1B1 | |
| SCHEMBL174847 | 0.82 | ADORA3 (0.67) | ADORA3KCNH2PDE5AGUCY1A1GUCY1B1 | |
| Hydrochloric Acid SCHEMBL1930775 | 0.81 | ADORA3 (0.66) | ADORA3KCNH2PDE5AGUCY1A1GUCY1B1 | |
| Hydrochloric Acid SCHEMBL18496411 | 0.81 | ADORA3 (0.66) | ADORA3KCNH2PDE5AGUCY1A1GUCY1B1 | |
| SCHEMBL255832 | 0.81 | ADORA3 (0.57) | ADORA3KCNH2PDE5AGUCY1A1GUCY1B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230381153-A1 | TREATMENT OF CNS DISEASES WITH sGC STIMULATORS | TISENTO THERAPEUTICS INC. | 2023-11-30 | — | — | US | disclosed |
| US-11690828-B2 | Treatment of CNS diseases with sGC stimulators | CYCLERION THERAPEUTICS, INC. (US) | 2023-07-04 | — | — | US | disclosed |
| US-11684621-B2 | Combination containing sGC stimulators and mineralocorticoid receptor antagonists | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2023-06-27 | — | — | US | disclosed |
| EP-2897953-B1 | SGC STIMULATORS | IRONWOOD PHARMACEUTICALS INC (US) | 2019-05-08 | — | — | EP | disclosed |
| EP-2588465-B1 | SGC STIMULATORS | IRONWOOD PHARMACEUTICALS INC (US) | 2017-01-25 | — | — | EP | disclosed |
| EP-3112363-A1 | 2-[1-[(2-FLUOROPHENYL)METHYL]-5-(3-ISOXAZOLYL)-1H-PYRAZOL-3-YL]-PYRIMIDINE DERIVATIVES AND RELATED COMPOUNDS AS SOLUBLE GUANYLATE CYCLASE (SGC) STIMULATORS FOR THE TREATMENT OF PULMONARY HYPERTENSION | Ironwood Pharmaceuticals, Inc. (US) | 2017-01-04 | — | — | EP | disclosed |
| EP-2797915-B1 | 2-benzyl-3-(oxazole/thiazole)-5-(pyrimidin-2-yl)-1(H)-pyrazole derivatives as stimulators of the soluble guanylate cyclase (sGC) for the treatment of e.g. hypertension or heart failure | IRONWOOD PHARMACEUTICALS INC (US) | 2016-07-13 | — | — | EP | disclosed |
| WO-2014047111-A1 | SGC STIMULATORS | IRONWOOD PHARMACEUTICALS, INC. (US) | 2014-03-27 | — | — | WO | disclosed |
| WO-2014047325-A1 | SGC STIMULATORS | IRONWOOD PHARMACEUTICALS, INC. (US) | 2014-03-27 | — | — | WO | disclosed |
| WO-2013101830-A1 | 2 - BENZYL, 3 - (PYRIMIDIN- 2 -YL) SUBSTITUTED PYRAZOLES USEFUL AS SGC STIMULATORS | IRONWOOD PHARMACEUTICALS, INC. (US) | 2013-07-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11690828-B2 | Treatment of CNS diseases with sGC stimulators | GUCY1A2, GUCY1B2, PDE2A | ADORA3 1070/4885KCNH2 2953/4885PDE5A 11/4885 |
| US-20230381153-A1 | TREATMENT OF CNS DISEASES WITH sGC STIMULATORS | GUCY1A2, GUCY1B2, PDE2A | ADORA3 1070/4885KCNH2 2953/4885PDE5A 11/4885 |
| US-11684621-B2 | Combination containing sGC stimulators and mineralocorticoid receptor antagonists | NR3C2, GUCY1A1, GUCY1A2 | ADORA3 785/4885KCNH2 1495/4885PDE5A 22/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.